Search for media from: "Bharathi Vennapusa"

NTRK fusions: Biology and Testing Methods

Dr. Denise Croix from Roche MSA discusses NTRK fusions biology and testing methods. Content and approvals of any product related info is current as of the date of publishing. TE-US-00861

From  Bharathi Vennapusa on November 20th, 2020 0 likes 23 plays

NTRK fusions: Testing Algorithms

Dr. Katie Robertson from Roche MSA discusses testing algorithms for NTRK fusion testing. Content and approvals of any product related info is current as of the date of publishing. …

From  Bharathi Vennapusa on November 20th, 2020 0 likes 22 plays

Interpretation of VENTANA pan-TRK (EPR17341) Assay - digital case review

Dr. Bharathi Vennapusa from Roche MSA reviews example cases stained with VENTANA pan-TRK (EPR17341) Assay using digital slides. Content and approvals of any product related info is current as of the…

From  Bharathi Vennapusa on November 20th, 2020 0 likes 19 plays

Pan-TRK IHC with VENTANA pan-TRK (EPR17341) Assay

Dr. Bharathi Vennapusa from Roche MSA discusses Pan-TRK IHC using VENTANA pan-TRK (EPR17341) Assay. Content and approvals of any product related info is current as of the date of publishing. …

From  Bharathi Vennapusa on November 20th, 2020 0 likes 15 plays

PD-L1 Testing and Developmental Process for Companion Diagnostic Tests

US Pathologist, Dr. Michael Lynch, from the Medical and Scientific Affairs (MSA) department for Roche Tissue Diagnostics discusses on: 1. The PD-L1 biomarker and its role in immunotherapy - time…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 13 plays

Tracking TRK with IHC: Today’s Diagnostic Algorithms for NTRK Testing: CAP Today Webinar by Dr. Weiss

Recording for Dr. Lawrence Weiss's talk on CAP Today Webinar from December 1, 2020. Title: Tracking TRK with IHC: Today’s Diagnostic Algorithms for NTRK Testing TE-US-00983

From  Bharathi Vennapusa on January 14th, 2021 0 likes 13 plays

PD-L1 Expression on Immune and Tumor Cells

US Pathologist, Dr. Michael Lynch, from the Medical and Scientific Affairs (MSA) department for Roche Tissue Diagnostics discusses: 1. How and why PD-L1 is present on tumor cells as well as being…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 12 plays

VENTANA PD-L1 (SP142) Assay

VENTANA PD-L1 (SP142) IHC assay is FDA-approved for mTNBC. Test for PD-L1 to identify patients who could benefit from TECENTRIQ + nab-pac in 1L mTNBC* This video is intended for US healthcare…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 11 plays

PD-L1 Testing and SP142 IHC Assay as a Diagnostic Tool in Urothelial Carcinoma

US Pathologist, Dr. Michael Lynch, from the Medical and Scientific Affairs (MSA) department for Roche Tissue Diagnostics discusses: 1. SP142 assay is optimized for staining for both immune and…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 10 plays

NTRK fusions: VENTANA pan-TRK (EPR17341) Assay

Drs. Bharathi Vennapusa, Denise Croix and Katie Robertson discuss overview of NTRK fusions, testing methods, algorithms with a focus on pan-TRK IHC assay using VENTANA pan-TRK (EPR17341) Assay. …

From  Bharathi Vennapusa on January 31st, 2021 1 likes 9 plays

CAP/ASCO HER2 2018 Guideline update and RocheHER2 Assays

Dr. Bharathi Vennapusa from Roche MSA discusses 2018 CAP/ASCO HER2 guideline update and how it pertains to Roche HER2 Assays. Content and approvals of any product related information is current as of…

From  Bharathi Vennapusa on November 20th, 2020 0 likes 8 plays

FDA classifications & Development of In Vitro Diagnostic Assays

Review of FDA classification of IVD assays, overview of clinical trial process as well as IVD development including analytical validation. TE-US-01092

From  Bharathi Vennapusa on March 16th, 2021 0 likes 8 plays

Tumor Microenvironment and PD-L1 biomarker

US Pathologist, Dr. Michael Lynch, from the Medical and Scientific Affairs (MSA) department for Roche Tissue Diagnostics discusses the tumor microenvironment, the cancer immunity cycle, the immune…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 7 plays

PD-L1 testing and SP142 assay as a diagnostic tool in triple negative breast cancer (TNBC)

VENTANA PD-L1 (SP142) assay is the first and only FDA-approved assay for mTNBC*. Testing for PD-L1 identifies patients who could benefit from TECENTRIQ + nab-pac in 1L mTNBC** This video is…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 7 plays

Case Study: Assessing PD-L1 in TNBC. Moderate IC staining without TC staining

Dr. Michael Lynch of Medical and Scientific Affairs for Roche Diagnostics reviews 3 cases that show the most common tissue staining pattern a pathologist will see in the triple negative breast cancer…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 7 plays

How to score the PD-L1 (SP263) Assay in Urothelial Carcinoma

US Medical and Scientific Affairs (MSA) pathologist Dr. Erin Marner provides an overview of the PD-L1 (SP263) Assay by reviewing two urothelial carcinoma cases. Common questions are addressed and…

From  Bharathi Vennapusa on December 2nd, 2020 0 likes 6 plays